Clinical Trial Update: SRT in Combination With Pembrolizumab in Patients With Recurrent Prostate Cancer After Radical Prostatectomy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating SRT in combination with pembrolizumab for recurrent prostate cancer after radical prostatectomy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biochemical Recurrence of Malignant Neoplasm of Prostate
• Prostate Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• SRT

Snippet

Sponsor: Prof. Dr. med. Christian Gratzke | Conditions: Urologic Cancer, Biochemical Recurrence of Malignant Neoplasm of Prostate | Phase 2 | Status: UNKNOWN